UNITY Biotechn…
ProfileJobs

UNITY Biotechnology

Suggest Edit
    • Healthcarebiotechpharmatherapy
    Unity Biotechnology, Inc. designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
    Market capitalization(2019-01-16)
    $674.2 M

    Employee Rating

    4.0More
    TypePublic
    HQSan Francisco, US
    Founded2009
    Size (employees)7 (est)
    Websiteunitybiotechnology.com
    UNITY Biotechnology was founded in 2009 and is headquartered in San Francisco, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at UNITY Biotechnology

    Keith R. Leonard

    Keith R. Leonard

    CEO
    Bob Goeltz

    Bob Goeltz

    CFO
    Nathaniel David

    Nathaniel David

    President
    Jamie Dananberg

    Jamie Dananberg

    Chief Medical Officer
    D. Dan Marquess

    D. Dan Marquess

    Chief Scientific Officer
    Tamara Tompkins

    Tamara Tompkins

    General Counsel
    Show more

    UNITY Biotechnology Office Locations

    UNITY Biotechnology has an office in San Francisco
    Show all (1)
    Report incorrect company information

    UNITY Biotechnology Financials and Metrics

    UNITY Biotechnology Revenue

    Market capitalization (16-Jan-2019)

    		674.2m

    Closing stock price (16-Jan-2019)

    		15.9
    UNITY Biotechnology's current market capitalization is $674.2 m.
    Show all financial metrics
    Report incorrect company information

    Competitors

    Syneos Health
    Healthcare - Public
    Deciphera Pharmaceuticals
    Healthcare - Public
    Innovation Pharmaceuticals
    Healthcare - Public
    Heron Therapeutics
    Healthcare - Public
    Compare competitors

    UNITY Biotechnology Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    UNITY Biotechnology News and Updates

    January 03, 2019

    UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye

    SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidat…
    September 05, 2018

    UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference

    SAN FRANCISCO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief executive officer, wil…
    Report incorrect company information

    UNITY Biotechnology Blogs

    December 04, 2018

    UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors

    UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors Content Import Tue, 12/04/2018 - 08:04 UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors December 4, 2018 at 8:00 AM EST This release is a backfill from a N…
    November 17, 2018

    Salim Sayed

    Salim Sayed ma.celeste.loy… Fri, 11/16/2018 - 19:47 Salim Sayed Mizuho Securities
    November 13, 2018

    UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence

    - Event will be webcast live - SAN FRANCISCO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will host an Investor &a…
    November 07, 2018

    UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results

    SAN FRANCISCO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported third quarter 2018 financial results.
    October 31, 2018

    UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results

    SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the third quarter ended September 30, 2018 , on
    September 24, 2018

    UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference

    UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference Content Import Mon, 09/24/2018 - 16:07 UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference September 24, 2018 at 4:05 PM ED…

    UNITY Biotechnology Company Life and Culture

    Report incorrect company information
    Download PDF

     UNITY Biotechnology Frequently Asked Questions

    • When was UNITY Biotechnology founded?

      UNITY Biotechnology was founded in 2009.

    • Who are UNITY Biotechnology key executives?

      UNITY Biotechnology's key executives are Keith R. Leonard, Bob Goeltz and Nathaniel David.

    • How many employees does UNITY Biotechnology have?

      UNITY Biotechnology has 7 employees.

    • Who are UNITY Biotechnology competitors?

      Competitors of UNITY Biotechnology include Syneos Health, Deciphera Pharmaceuticals and Innovation Pharmaceuticals.

    • Where are UNITY Biotechnology offices?

      UNITY Biotechnology has an office in San Francisco.

    • How many offices does UNITY Biotechnology have?

      UNITY Biotechnology has 1 office.